Somatostatin analogs have 2 roles in gastroenteropancreatic neuroendocrine tumors (GEP-NETS): treating symptoms related to the tumors and controlling tumor growth, explained Heloisa Soares, MD, assistant professor, University of New Mexico Cancer Center-Albuquerque.
Somatostatin analogs have 2 roles: treating symptoms related to gastroenteropancreatic neuroendocrine tumors (GEP-NETS) and controlling tumor growth, explained Heloisa Soares, MD, assistant professor, University of New Mexico Cancer Center-Albuquerque.
TranscriptHow have somatostatin analogs enhanced the treatment landscape of gastroenteropancreatic neuroendocrine tumors?
So, somatostatin analogs are extremely important. They have 2 roles. They have the role to treat symptoms related to these tumors because many of these tumors will secrete hormones, and we can control some of that with the use of somatostatin analogs. But, it’s also very important as a treatment in terms of controlling tumor growth. We know from the CLARINET and the PROMID trials that the use of somatostatin analogs as first-line treatment in the metastatic setting or in patients with locally advanced disease delays tumor growth of these tumors.
So, it’s extremely fundamental for the treatment landscape of neuroendocrine tumors, the use of somatostatin analogs.
How does sequential treatment with these therapies impact clinical outcomes?
We typically use somatostatin analogs as the first line for patients, and the general consensus in the neuroendocrine tumors field is that they are very interchangeable. So, you start with one, and then when you progress, you should change classes of treatment. However, there is some interesting new data, a retrospective analysis coming out and saying that perhaps there might be a role to switching somatostatin analogs before jumping to a completely different class of therapies.
We truly don’t know that, so for the time being, so we typically will use 1 of the 2 commercially available somatostatin analogs as the first line, and then at the time of progression, if you’re just doing it for tumor control and patients don’t have any symptoms, then you will switch to a completely different class of treatment or intervention. But, I’m very interested in this new data coming out that perhaps there might be a role of sequention with somatostatin analogs. It’s too early to tell, but we’ll see when more studies come out.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More